Rats bearing the Yoshida AH-130 ascites hepatoma showed enhanced fractional rates of protein degradation in gastrocnemius muscle, heart, and liver, while fractional synthesis rates were similar to those in non-tumor bearing rats. This hypercatabolic pattern was associated with marked perturbations of the hormonal homeostasis and presence of tumor necrosis factor in the circulation.
Introduction
Loss ofbody weight and cachexia are common signs associated with neoplastic diseases. Cachexia is a poorly understood syndrome characterized by anorexia, profound metabolic abnormalities, and progressive host wasting that results in death ( [1] [2] [3] . Tissue wasting mainly involves skeletal muscles and adipose tissue. Numerous reports attribute the development ofthe cachectic state to the release of cytokines, such as TNF (for a review, see reference 4).
TNF is primarily produced by activated macrophages in response to invasive stimuli. It belongs to a polypeptide network made up ofseveral cytokines and growth factors that have wide and varied effects on the growth, differentiation, and functions of the immune system, as well as of other cells and tissues (5, 6) . Chronic treatment of rats with recombinant TNF results in depletion of body protein, as compared with pair-fed control animals (7) , and redistribution of body protein associated with significant muscle protein depletion and coordinated decreases in muscle mRNAs for myofibrillar proteins (8) . The administration of recombinant TNF enhances the nitrogen efflux from skeletal muscle in non-weight losing humans with disseminated cancer (9) , as well as muscle protein breakdown in rats (10) . In vitro proteolytic rates in muscles isolated from rats receiving a single dose ofTNF have been reported either unchanged (I I) or increased ( 12) .
Rats bearing the ascites hepatoma Yoshida AH-130 offer a suitable model system for investigations into the mechanisms that lead to cancer cachexia. Previous work has shown that tumor growth rapidly elicits in the host rat a conspicuous body weight loss associated with a hypercatabolic state in tissue protein ( 13, 14) . Marked perturbations in the hormonal homeostasis develop early after tumor implantation, together with increased levels of prostaglandin E2 and detectable TNF in plasma ( 15) . It thus appeared of interest to explore the role played by TNF in this experimental model of cancer cachexia. The aim ofthe present investigation was to evaluate the involvement of this cytokine in mediating the changes in muscle protein turnover in AH-130 tumor-bearing rats through the administration ofa goat polyclonal anti-murine TNF IgG. Such a treatment both abolished any detectable free TNF in the plasma and afforded a significant preservation of muscle protein, thus supporting a causative role for TNF Polyclonal goat anti-murine TNF IgGs were prepared using the Ribi adjuvant system containing 0.5 mg each of monophosphoryl lipid A, trehalose dimycolate, and cell wall skeleton in 0.2% Tween 80 (Ribi ImmunoChem. Res., Inc., Hamilton, MT). The serum IgG fraction was obtained by polyethylene glycol precipitation and column chromatography with DEAE Bio-Gel A (Bio-Rad Laboratories, Richmond, CA). The neutralizing capacity of the anti-TNF IgG fraction in the L929 cytotoxicity assay was 6.5 and 9.0 X 105 50% neutralizing units/ mg IgG against recombinant MiTNF-a and serum TNF from LPStreated rats, respectively. Nonimmune goat IgGs were prepared in the same way and had no detectable TNF neutralizing activity (16) . Neither IgG preparation demonstrated effective binding to LPS, IL-1, or interferon-y in an ELISA protocol.
Plasma metabolites. Circulating insulin and corticosterone were determined using the insulin (Coming Inc., Medfield, MA) and the rat corticosterone (IDS, Boldon, England) radioimmunoassay kits, respectively. Plasma TNF was measured using both the L929 cytotoxicity assay (17) and an ELISA test (Genzyme Corp., Cambridge, MA). Anti-TNF titers were estimated using an ELISA test (16) .
Tissueprotein turnover. In vivo protein turnover was determined as previously described (13) . For this purpose, animals were injected intraperitoneally with 400,gCi/kg body wt with NaH 14CO3, dissolved in 0.15 M NaCl, 24 h before time 0, and killed on days 0, 4, and 7 after tumor inoculation. Liver, kidneys, gastrocnemius, and heart were rapidly weighed and homogenized to 10% (wt/vol) in chilled water and then frozen to -20°C. Total protein content was determined by the method of Lowry et al. (18) . Trichloroacetic acid-insoluble proteins were processed for lipid extraction, extensively hydrolyzed, and counted in a liquid scintillation spectrometer (cf 13). Total and specific (per milligrams of protein) protein radioactivity were determined for gastrocnemius muscle, heart, kidneys, and liver. Fractional rates of protein synthesis (kA), protein degradation (kd), and protein accumulation (kA) were calculated (19, 20) by the following equations: k, = ln (specific protein radioactivity)t-' kd = ln (total protein radioactivity)t-' kA = ln (total protein)t' kA, = k, -kd and expressed as percent per day, while t/12 (=ln 2/kd) was given in days. The procedure adopted in studying protein radioactivity decay, with time 0 corresponding to 24 h after administration of the label, only takes into account the long-lived pool of tissue proteins, which represents the large majority of the protein mass.
Data presentation. Data are means±SEM. Significance of the differences was calculated by analysis of variance. 
Results
Tumor growth and body weight. The Yoshida AH-130 ascites hepatoma is a fast growing tumor: after an inoculum of 108 cells, the growth was exponential for 4-5 d with a population doubling time of 23 h, followed by a stationary phase from day 7 until death ofthe animals (cf 13). By day 4 after inoculation, the tumor-bearing rats exhibited a diminished gain in body weight, and by day 7, their body weights were less than their initial body weights (Table I) . During this period, there was a progressive increase in tumor volume (Table I ). The anti-TNF treatment did not significantly affect such changes.
The tumor mass (total cell wet weight) represented only 2.0 and 4.7% of host body weight on days 4 and 7, respectively. Thus, changes in body weight can not be explained by growth oftumor mass by itself. The number oftumor cells was moderately decreased on day 4 in anti-TNF-treated animals, but this effect was transient and not present on day 7 (Table I) .
Anti-TNF titer, TNF level, and plasma hormones. Anti-TNF antibodies and TNF were measured in the plasma and ( 15) . In the ascitic fluid TNF attained levels 53-60% higher than in serum (Fig. 2) , as one would expect ifit was mainly produced intraperitoneally (cf 15). The administration ofanti-TNF antibodies abolished any detectable free TNF in both serum ( Fig. 1 ) and ascitic fluid (Fig. 2) , while nonimmune IgGs had no effect. Plasma insulin decreased while corticosterone increased in response to tumor growth (Fig. 3 (22) . However, fractional rates of protein accumulation obtained by difference between fractional rates of synthesis and degradation (kal = ks -kd) usually approximately match those calculated directly from changes in total protein (ka), as shown in Table III . The 24-h lag between the administration of NaH '4CO3 and the first experimental time (day 0 of tumor growth) was adequate to exclude from measurements the fast turnover protein pool, as well as secretory proteins; thus, this experimental protocol only evaluates the slow-turnover protein pool(s) ( 13 ) . The protein turnover rates and the t/2 measured over the two observation windows (days 0-4 and days 4-7, respectively) were quite different for liver and kidney because ofthe heterogeneous half-lives ofproteins of the slow turnover pool(s) (cf 23), while they were practically identical for muscle and heart; therefore, only data for the 0-7-d interval are presented for skeletal muscle and heart.
The effects of the anti-TNF treatment on protein synthesis and degradation in muscle and other tissues of tumor bearers are summarized in Table III . The skeletal muscle, which represents the major protein mass, was markedly affected in AH-130 tumor-bearing rats. Protein waste implies an imbalance between synthesis and degradation. While the fractional synthesis rates (ks) showed little change in the gastrocnemius and heart as a result oftumor growth, fractional rates of protein degradation (kd) were markedly elevated, viz, 2.5-fold for gastrocnemius and 2.6-fold for heart, thus protein losses (ka, and ka) in both tissues have to be mostly accounted for by the latter change. The anti-TNF treatment decreased protein degradation in the gastrocnemius, as compared with the animals receiving nonimmune IgGs and, as a result, protein accumulation was improved, although the values were still lower than in non-tumor bearers. Surprisingly, anti-TNF antibody and nonimmune IgGs had similar effects in slowing down protein degradation and improving protein accumulation in the heart. In the liver, a slight increase in synthesis rates and an important increment in degradation rates were observed for both 0-4-d and 4-7-d intervals after tumor transplantation; consequently, the hepatic protein mass was markedly affected. The anti-TNF treatment decreased both synthesis and degradation rates to a similar degree in the first interval (0-4 d) so that protein loss was not evident. The anti-TNF treatment produced a marked reduction in protein degradation in the second observation period (4-7 d) to rates that were not different from those measured in non-tumor bearing controls. Liver protein was thus significantly preserved. Similar results occurred in the kidneys, but the effects of the anti-TNF treatment were less pronounced in this tissue.
Discussion
TNF has been proposed as an important mediator of cachexia (4, 5, 24, 25) . Its role in cancer cachexia has been very controversial. No significant correlation was observed between severity of weight loss and serum TNF levels in cachectic patients (26) . When given repeated injections of TNF, experimental animals develop tachyphylaxis, i.e., become progressively desensitised to the anorectic/cachectic action of the cytokine, and increasing daily doses ofTNF are required to maintain the same effects (7). This phenomenon does not occur, however, if TNF is given by continuous infusion rather than by sporadic injections (27) or in nude mice implanted with Chinese hamster ovary cells transfected with the human TNF gene, which thus develop a profound cachectic state (28) .
The ascites hepatoma Yoshida AH-130 causes early and progressive tissue waste in the host rats, by producing an unbalance in protein turnover towards the catabolic side ( 13 ) . Such a pattern is associated with marked alterations in the hormonal homeostasis and occurrence of persistent TNF levels in the circulation ( 15) . The present paper shows that administration of anti-TNF antibodies to these rats neutralized circulating TNF, thus making this a particularly interesting model to examine its possible involvement in cancer cachexia. A note of caution is suggested by the observation that the anti-TNF treatment resulted in a transient, slight reduction in the tumor cell number 4 d after transplantation. Whether this reflected the decreased availability of TNF as a possible autocrine growth factor for these tumor cells (cf 15) or a diminished availability of nutrients (cf 29) caused by the anticatabolic effects of the anti-TNF treatment or some other mechanism, it is difficult to establish at the moment. However, the observed reduction in tumor size on the one hand was too small to have exerted any significant effect on host metabolism (cf 13), on the other was quickly overcome and no longer detectable on day 7 of tumor growth.
In a another paper (Carbo, N., P. Costelli, L. Tessitore, G. J. Bagby, F. J. Lopez-Soriano, F. M. Baccino, and J. M. Argiles, submitted for publication), we have shown that treatment with anti-TNF antibody significantly interfered with the development of perturbations of lipid metabolism and adipose tissue waste in AH-130 tumor-bearing rats. The present observations further show that treating the AH-130 tumor-bearing animals with anti-TNF antibody had appreciable effects on protein turnover in all of the tissues examined, namely, gastrocnemius, heart, liver, and kidney. In general, the anti-TNF treatment was adequate to decrease the enhanced rates of protein degradation. By contrast, synthesis rates were little or negligibly affected by tumor growth and the anti-TNF treatment did not introduce any change, except in the liver, wherein a decrease in the synthesis rate was observed. Although not detected in the present experiments, likely because of the single time point selected (day 4), a transient enlargement of the liver during the very first days of AH-130 tumor growth is usually observed: a change associated with enhanced protein synthesis ( 13) . This may reflect, in part at least, an acute phase reaction (see below). The reduction in hepatic protein synthesis afforded by the anti-TNF treatment may thus correspond to an interference with the late stages of such changes. In spite of the improved protein turnover patterns observed in all tissues examined, only the gastrocnemius benefitted with a significant preservation ofprotein mass by the anti-TNF treatment in comparison with untreated or nonimmune IgG-treated tumor bearers. Moreover, the anti-TNF treatment did not afford any significant preservation of the body and carcass weight. Although the present data do not provide any clue to account for this apparently paradoxical finding, a decreased water retention in anti-TNF-treated rats seems a likely explanation (cf 7, 24, 30) . The fact that the anti-TNF treatment has greater effects in the early phases of tumor growth as compared to late strongly suggests that TNF is not the only mediator involved in cachexia. The effects exerted by the anti-TNF antibodies administration, in particular the delaying of the decrease in insulin and increase in corticosterone plasmatic levels (cf 15), also support the idea that this cytokine may be important during the first days after tumor transplantation, probably altering the hormonal homeostasis towards a catabolic pattern.
The present observations strongly support an involvement of TNF in the development of cancer cachexia and, in particular, a role for this cytokine in mediating the alterations of protein metabolism. This is in keeping with previous reports on rats transplanted with a methylcholanthrene-induced sarcoma and rendered tolerant to TNF through repeated administrations of low doses of the cytokine (31 ) or on mice bearing the sarcoma MCG-101 treated with anti-TNF antibodies (32). Of interest, in the latter model, tumor cells themselves produced the cytokine, yet cachexia developed without any measurable plasma TNF (33) , suggesting that this mediator might be important even at concentrations below the present levels of detectability.
A role for TNF in altering tissue protein metabolism has been suggested by a number of reports. Thus, a single dose of recombinant human TNF to rats resulted in increased muscle proteolysis ( 10) , while rats given the cytokine on a chronic schedule lose total body protein at rates higher than pair-fed controls (7) . TNF administration augmented the amino acid release from peripheral tissues in cancer patients (9) , and muscle protein degradation was accelerated by TNF given at doses smaller than those required to produce hemodynamic changes (34) . In vitro work also seems to implicate TNF in enhancing protein degradation ( 12) , although evidence for its direct mediation of this effect remains elusive (1 1, 35, 36 ). In the liver, TNF is able to enhance protein synthesis (37), to increase the proportion of mRNA species for serum albumin and acute phase proteins (38) , and to stimulate the uptake of a-aminoisobutyrate, a nonmetabolizable analogue of alanine (39) .
It has been suggested that TNF may accelerate muscle protein catabolism by stimulating the release of adrenocortical hormones or interacting with them (40, 41 ) . Such a possibility is compatible with the high levels ofcorticosterone occurring in rats bearing the Yoshida AH-130 hepatoma ( 15) , as well as with their reduction on anti-TNF treatment, as shown by the present data. The same possibility applies to insulin, which markedly decreased in tumor bearers and was partially or totally restored to normal levels by the anti-TNF treatment. In this regard, the concurrent administration of insulin with TNF was shown to modulate the toxic effects ofTNF on rats (27) . In principle, an improvement in the nutritional state of tumor hosts could have been a predictable consequence of the anti-TNF treatment, yet the food intake in anti-TNF-treated animals was not increased with respect to untreated or nonimmune IgG-treated experimental groups, thus ruling out this possible explanation for the anti-TNF effects. This finding provides further support to the view, derived from our previous work, that decreased food intake is unlikely to play a primary role in the development of cachexia in AH-130 tumor hosts ( 15) . The only exception was the heart, wherein protein loss in tumor bearers was comparable to that in pair-fed controls ( 14) .
The results presented here definitely implicate TNF in the changes of protein metabolism associated with the growth of the Yoshida AH-130 hepatoma. However, in these as well as in other experiments (Carbo, N., P. Costelli, L. Tessitore, G. J. Bagby, F. J. Lopez-Soriano, and J. M. Argiles, manuscript submitted for publication) the anti-TNF treatment was far from affording a complete protection, not even in the initial phases of tumor growth. Other humoral factors have been postulated to concur in mediating cancer cachexia in other models. Among the most recent reports, severe cachexia is induced by a muscle proteolytic factor produced by the murine colon adenocarcinoma MAC 16 (42) or develops in nude mice implanted with different melanoma cell lines producing the leukemia inhibitory factor (43) or with Chinese hamster ovary cells transfected with human IFN-,y cDNA (44) . Moreover, Matthys et al. (45) have observed that the development of cachexia in mice bearing the Lewis lung carcinoma can be prevented by the administration of anti-IFN-'y antibodies. Therefore, the present observations by no means can lead to the conclusion that TNF is the sole mediator of cancer cachexia, not even in the present model system.
